PLAN B ONE-STEP OTC
Generic Name and Formulations:
Levonorgestrel 1.5mg; tabs.
Indications for PLAN B ONE-STEP:
Prevention of pregnancy after known or suspected contraceptive failure or unprotected intercourse. Not for use as regular contraceptive.
Rule out pregnancy first. Take one single-dose as soon as possible but no later than 72hrs after unprotected intercourse. If vomiting occurs within 2hrs, may consider repeating dose.
See full labeling. Known or suspected pregnancy.
See full labeling. Ectopic pregnancy. Does not protect against HIV or other STDs.
May be antagonized by CYP3A4 inducers (eg, efavirenz, rifampin, barbiturates, carbamazepine, phenytoin, St. John's wort).
Heavier menstrual bleeding, nausea, vomiting, abdominal pain, fatigue, headache, dizziness, breast tenderness, delay of menses (>7days).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|